Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 4;11(1):2689–2697. doi: 10.1080/22221751.2022.2132881

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Comparison of neutralizing antibody titre among all groups. (a) Levels of NAbs against WT and Omicron BA.1 before immunization. (b) Neutralizing antibody titres against SARS-CoV-2 WT and Omicron variants BA.1 strains in all groups at day 28. The NAbs titre in each group is shown as the GMT at the top of each panel, and factor differences from WT to Omicron BA.1 subvariants are indicated. p-values for group differences are shown above each group. (c) Comparison of 13G2 neutralizing titre among all groups at 7, 14 and 28 days after third dose administration. (d) Comparison of 08B3 neutralizing titre among all groups at 7, 14, and 28 days after third dose administration. Portion of NAbs represented by monoclonal antibodies 13G2 (e) and 08B3 (f) compared to neutralizing antibody for all groups at day 28. p-values for group differences are shown above each group.